Purpose: Our prior study found that pharmaceutical-sponsored and non-profit sponsored analyses differed in their published assessments of the economic value of six new oncology drugs. In this study, we expand on our earlier findings and evaluate the association between funding source and 1) characteristics of the published study report and 2) journal type for dissemination of the previously evaluated economic studies.
Introduction
With constant financial pressures on health care providers, pharmacoeconomic analyses have increased in frequency over the past decade [I, 2] . However, the usefulness of this literature has been questioned [3, 4] and caution has been advised as many reports fail to adhere to fundamental analytic principles [3] . Reviews of studies from the 1980s and early 1990s found that the majority of economic analyses had substantial limitations [2, 3, [5] [6] [7] [8] . In an effort to improve the quality of economic evaluations, several organizations and countries produced guidelines for study design and reporting [2, 9] .
In one such effort, the British Medical Journal published formal guidelines for the acceptance of economic analyses for publication. Rather than improving reporting quality, however, implementation of the guidelines served only to streamline the journal's editorial process [10] .
Clinical trials, which provide the data upon which economic analyses are based, have over the past 20 years been funded more often by pharmaceutical companies [11, 12] . There is concern about the reporting of such pharmaceutical sponsored clinical trials [13] . Johansen and Gotzsche found that inappropriate methods in pharmaceutical sponsored studies led to over-estimates of the clinical benefits of a new antifungal agent, raising concerns about the quality of design and reporting of these studies [13] . We recently found empirical support for an alternative explanation in the setting of clinical trial reports, in which pharmaceutical-sponsored efforts focused a priori on settings where favorable results would be expected [14] .
Similar concerns exist with respect to the pharmacoeconomic literature. Economic analyses are far more likely to describe new agents as cost-effective when the study is sponsored by a pharmaceutical firm [15, 16] . Azimi and Welch reported that pharmaceutical sponsored cost-effectiveness studies found new agents to be cost-effective using thresholds that were significantly greater than those included in not-for-profit sponsored studies [15] . We found that pharmaceutical sponsored studies of six new agents used in oncology were nearly eight times less likely than nonprofit sponsored studies to report an unfavorable conclusion about the costeffectiveness of a new agent [16] . One interpretation of these findings, based on the popular press [17] and the pharmacoeconomic literature [13, 18] suggests that sponsored pharmacoeconomic literature may differ in reporting details as well as the quality of journal selected for dissemination. An alternative explanation is selective funding, reporting, or publishing of favorable pharmacoeconomic studies. As a continuation of the research outlined in our studies of pharmaceutical sponsored clinical and economic reports [14, 16] , we formally evaluated the association between pharmaceutical versus non-profit funding source of economic studies in oncology and 1) general aspects of economic study reporting and 2) preference for publication in lower impact journals. The data set included the 44 economic studies used in our earlier study [16] . Reporting assessments were based on generally accepted criteria adapted from the recently published report from the US Panel on Cost Effectiveness in Health and Medicine [19] [20] [21] .
Methods
The primary objective of this study was to evaluate the general reporting characteristics of all of the published pharmaceutical-and nonprofitsponsored economic literature for six novel drugs in oncology. A secondary objective was to evaluate whether pharmaceutical and nonprofit sponsored studies differed in the frequency with which their findings were disseminated in peer-reviewed journals with a large readership of oncologists and policy makers. Our data set for these studies consisted of the 44 economic analyses used in our previous report that identified potential conflicts of interest in pharmaceutical sponsored studies [16] . In these studies, we reviewed original reports of cost and cost-effectiveness analyses published from 1988-1998 of six recently-marketed cancer drugs (hematopoietic growth factors (granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor); seratonin antagonist antiemetics (ondansetron hydrochloride and granisetron); and taxane chemotherapy agents (paclitaxel and docetaxel).
A nine-item instrument for evaluating pharmacoeconomic reports was developed for this study. The instrument was based on the guidelines for economic analyses recently published by the US Public Health Service Panel on Cost Effectiveness in Health and Medicine [19] [20] [21] . The instrument contained items related to reporting of study methods, generalizability of findings, and background/conclusions sections of the study. Reporting assessments were based on the following nine items: 1) a rigorous clinical design (randomized with a control if based on a clinical trial or assumptions well-described if based on a model), 2) generalizable data sources (sensitivity analyses of at least three variables or trial costs modified to represent standard use). 3) statistical tests of significance performed on appropriate outcomes (resulting in a P-value). 4) a statement regarding perspective, 5) a description of the costs of the main included resources, 6) a description of the time horizon, 7) a description of the source of total cost differences including a breakdown of cost areas. 8) a discussion of the limitations, and 9) comparisons to other published studies. No attempt was made to qualitatively evaluate each item further than to establish that each item was addressed or present.
To evaluate the secondary objective related to publication sources of pharmaceutical-and non-profit sponsored economic studies, dissemination was evaluated using the journal impact factor statistic. This statistic is reported for each journal in the 1996 edition of the Science Citation Index Journal Citation Reports (JCR) published by the Institute for Scientific Information. The journal impact factor is a measure of the frequency and timeliness with which an average article from a particular journal is cited.
Two investigators (J. R. Adams and K.. S. Knox) independently abstracted information from each of the articles using the instrument described above. Articles were classified as either pharmaceutical company-sponsored or nonprofit-sponsored (government agency, professional organization, nonprofit foundation, or academic institution). As noted previously, we obtained complete information on source of funding for each study [16] . Investigators abstracting quality aspects were blinded to the funding source. Disagreements over scores were reconciled by consensus during discussion with a third investigator. The quality scores were compared to a derived overall nine-point sum total representing the presence/absence of each individual quality measure. Impact values were also compared based on sponsorship type. Because the study is based on reviews of the entire population of pharmacoeconomic analyses of the six drugs rather than a sample of studies, formal statistical tests of differences are not reported.
Results
The 44 economic analyses represent the entire body of published pharmacoeconomic literature for the 6 oncology drugs. The studies varied in reporting detail. The percentage of pharmaceutical or non-profit sponsored studies adhering to any given reporting criteria ranged from 20% to 90% (Table 1) . Most studies contained detailed information related to study methods, including identification of specific areas of cost savings and detailed explanations of model design or rigorous clinical design. In contrast, less frequently described method areas related to study generalizability. Pharmaceutical-and non-profit sponsored studies differed with respect to compliance with individual reporting considerations. Pharmaceutical-sponsored studies were more likely to include information reported from randomized controlled trials or detailed cost-models (90% vs. 70%), to clearly describe the source of cost differences (90% vs. 79%), to state whether the study was carried out from a societal, governmental, or insurer perspective (70% vs. 42%), and to clearly indicate the time-period over which costs were evaluated (65% vs. 50%). Nonprofit sponsored studies were more likely to include information about how the data could be extrapolated to other clinical settings (58% vs. 35%), to include a statistical comparison of the results (38% vs. 20%), and to clearly outline costs per unit and data sources for the cost analyses (67% vs. 45%). Pharmaceutical and non-profit sponsored studies were similar with respect to providing literature comparisons of the results (about 80%) and discussing the limitations of the finding (75% for pharmaceuticalsponsored and 67% for non-profit sponsored studies). A majority of the economic analyses was published in journals with low journal impact factors. These low impact factor journals are generally targeted to limited readerships, primarily pharmacy, supportive care, and oncology subspecialty audiences ( Table 2) . Distributions of journal impact factor scores were similar between pharmaceutical versus nonprofit-sponsored studies (Figure 1) .
Discussion
This study investigated the association between pharmaceutical company sponsorship and study reporting and dissemination of findings in the peer-reviewed literature. In particular, we found that the body of literature for pharmaceutical-sponsored and non-profit sponsored economic studies for six new oncology drugs differed in specific aspects of reporting, but were disseminated in journals with similar target readership audiences. Pharmaceutical-sponsored economic analyses were less likely overall to formally report on study generalizability, but were more likely to provide information on the key components of the methods section, including detailed information about data sources and the duration of the observation period. Our findings may help explain the observed bias in the pharmacoeconomic literature. Having detailed methods sections, the primary advantage noted in pharmaceuticalsponsored studies, facilitates interpretation of the validity and reliability of the cost estimates. In contrast, extensive reporting of generalizability, the primary advantage noted in non-profit sponsored studies, is essential if analyses are to be extrapolated from clinical trial or decision analytic modeling settings to routine clinical practice settings. However, even after reviewing the entire pharmacoeconomic literature for six new oncology drugs, one of the main study questions remains unanswered. In particular, we were not able to evaluate whether pharmaceutical sponsorship directly impacted the likelihood that unfavorable reports would not be submitted for publication. This concern has been raised previously as one of the main reasons for infrequent publication of unfavorable pharmaceutical-sponsored studies [14, 16] . Since decision making is based on physician interpretation of published data, underreport-Impact Factor by sponsorship* ing research has been condemned as a form of scientific misconduct [25] . By not publishing some results, misperceptions can arise about treatment efficacy, safety and cost-effectiveness [25] [26] [27] [28] . Journal editors have proposed establishing an international registry of randomized trials in order to reduce the impact of underreporting and publication bias on clinical trials [26] . Our study provides further rationale for establishing a register of ongoing trials, including pharmacoeconomic analyses. Our results suggest that journal editors viewed pharmaceutical and non-pharmaceutical sponsored pharmacoeconomic studies as less relevant in comparison to clinical articles. The majority of industry and non-profit sponsored studies appeared in journals with low impact factor scores targeted to pharmacy, supportive care, and oncology subspecialty audiences. Nonetheless, pharmaceutical sponsored studies tended to appear in journals targeted to pharmacists and non-profit sponsored studies tended to appear in journals targeted to physicians.
While our study sample for six new oncology drugs spanned a ten-year publication period, this body of literature was not large enough nor published over a long enough time-period to detect a difference in study reporting over time. Inferences on this subject can be made after reviewing other reviews of economic analyses reported in the previous decade. While almost 70% of the model-based economic evaluations from the 1990s reviewed in our study reported detailed sensitivity analyses, overview studies of cost-effectiveness articles from the years 1978-1994 found that only 6%-30% included information on sensitivity analyses [3, 5, 6] One half of the studies reported whether the analyses were based on a societal, insurer, or patient perspective [2, 7] , whereas only 18% of articles surveyed in the 1970s and 1980s included similar information [3] . These findings suggest that study methods for economic studies may be improving over time. Continued improvements in several aspects of study reporting are needed to improve the overall credibility of the economic literature.
Our study has several limitations. First, the review measures that we used do not represent a validated checklist. However, the framework of the US Panel on Cost Effectiveness in Health and Medicine [19] [20] [21] , from which we derived our design and reporting measures, is widely accepted today and represents a synthesis of study methods that have been developed over the past two decades. Second, we considered only one type of economic relationship between industry and researchers: direct funding of the analysis reported. Researchers often receive other types of financial and non-financial support, including honorarium, consultation, and travel expenses. Third, the impact factor scoring system is an imperfect measure of the size of audience of a particular journal, and bore no relationship to the methodologic quality of individual studies. Nonetheless, the journals with high impact factor scores included in our study were targeted to general medical audiences and hematology and oncology specialty society members, and those with the lowest impact factor scores were targeted to pharmacy, supportive care, and oncology subspecialty readerships. Finally, while the number of articles in our study is small, it represents the entire population of costeffectiveness analyses in the three important oncology markets. As such, a larger study addressing cost studies for these drugs is not possible, nor is it necessary. Finally, the choice of drugs in our study was based on data on pharmacy expenditures obtained from several cancer centers. Additional reviews of cost-effectiveness articles for other expensive pharmaceuticals is warranted in order to evaluate the generalizability of our findings.
In conclusion, these results add to our prior insights about differences in the published literature between pharmaceutical-and non-profit sponsored economic studies. Pharmaceutical-sponsored cost studies for six new oncology drugs, as a consequence of relatively low rates of inclusion of detailed reports on study generalizability, tended to highlight specific clinical settings where the study drugs were cost-effective and left open questions about cost-effectiveness in other routine clinical practice settings. Additional studies are needed to see if this difference in focus applies to pharmacoeconomic studies of other oncology drugs and accounts in part for the lower likelihood of finding unfavorable results in the pharmaceutical-sponsored literature.
